CEO Sam Altman noted in 2023 that the company may look into a “sign in with OpenAI” feature in 2024. However, it now appears OpenAI is more seriously building out the capability today, in 2025.

Vor Biopharma Inc. (NASDAQ:VOR) is one of the hot penny stocks to invest in now. In a report released on June 30, Swayampakula Ramakanth from H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ ...

Vor Biopharma pivots to telitacicept with $175M funding, eyeing multi-billion potential. Risks include dilution, regulatory hurdles, and operational challenges. Read more on VOR.

Zinger Key Points Vor inks $125M global license deal for autoimmune drug telitacicept. Company secures $175M through PIPE, appoints Jean-Paul Kress CEO. The next correction is closer than you think.